Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.39 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 2/20 | 0.37 |
| ▸ | KLK1 | P06870 | 2/20 | 0.37 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10359086 | 0.98 | CYP2C19 (0.39) | CYP2C19NR5A2NR5A1PLGKLK1 | |
| Dimethylamine SCHEMBL11342588 | 0.96 | NR5A2 (0.39) | CYP2C19NR5A2NR5A1PLGKLK1 | |
| SCHEMBL6330116 | 0.92 | CYP2C19 (0.35) | CYP2C19NR5A2NR5A1PLGKLK1 | |
| Glycolic Acid SCHEMBL9813127 | 0.92 | PLG (0.35) | CYP2C19NR5A2NR5A1PLGKLK1 | |
| SCHEMBL11343552 | 0.88 | ALDH1A1 (0.42) | CYP2C19NR5A2NR5A1PLGKLK1 | |
| Hydrochloric Acid SCHEMBL11353350 | 0.87 | HPGD (0.41) | CYP2C19NR5A2NR5A1PLGKLK1 | |
| SCHEMBL11342901 | 0.86 | CYP2C19 (0.39) | CYP2C19NR5A2NR5A1PLGKLK1 | |
| SCHEMBL11345518 | 0.85 | NR5A2 (0.44) | CYP2C19NR5A2NR5A1PLGKLK1 | |
| Hydrochloric Acid SCHEMBL11349325 | 0.85 | CYP2C19 (0.38) | CYP2C19NR5A2NR5A1PLGKLK1 | |
| Hydrochloric Acid SCHEMBL11345903 | 0.84 | NR5A2 (0.43) | CYP2C19NR5A2NR5A1PLGKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | LEVY ANDREW | 2009-02-26 | — | — | US | claimed |
| WO-2008153908-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF INTRAPLAQUE HEMORRHAGE | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2008-12-18 | — | — | WO | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| US-6444221-B1 | ADMINISTERING AMINOBENZOIC ACID | SECANT PHARMA, LLC | 2002-09-03 | — | — | US | claimed |
| EP-0707446-A4 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 2001-01-10 | — | — | EP | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| JP-H08512055-A | — | — | 1996-12-17 | — | — | JP | claimed |
| EP-0707446-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO, Howard, K. (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995001096-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1995-01-12 | — | — | WO | claimed |
| US-4245099-A | ANTIINFLAMMATORY, ANALGESIC, DIURETIC, ANTIPYRETIC AND HYPOTENSIVE AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1981-01-13 | — | — | US | claimed |
| JP-62059209-A | — | — | None | — | — | JP | disclosed |
| US-20250304667-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3693381-B1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2025-09-03 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995001096-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1995-01-12 | — | — | WO | disclosed |
| JP-S6259209-A | ANTIARTERIOSCLEROTIC AGENT CONTAINING 2-AMINOMETHYLPHENOL DERIVATIVE AS ACTIVE CONSTITUENT | ONO PHARMACEUT CO LTD | 1987-03-14 | — | — | JP | disclosed |
| US-4245099-A | ANTIINFLAMMATORY, ANALGESIC, DIURETIC, ANTIPYRETIC AND HYPOTENSIVE AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | APOB, PPHLN1, SERPINC1 | CYP2C19 2150/4885NR5A2 3339/4885NR5A1 3597/4885 |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | CYP2C19 611/4885NR5A2 4281/4885NR5A1 3245/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | CYP2C19 712/4885NR5A2 4473/4885NR5A1 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.